A randomized trial of exercise versus control for musculoskeletal symptoms from adjuvant anastrozole (A) for postmenopausal early breast cancer (PEBC).

• DOI: 10.1200/jco.2011.29.15_suppl.636
• Publication Date: 2017-02-23T13:58:03Z
• Authors: C. A. Lohrisch; D. McKenzie; P. Truong; D. Jesperson; K. A. Gelmon; S. Premji; H. F. Kennecke
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

636 Background: Musculoskeletal symptoms, for which there is no standard therapy, are common in women on aromatase inhibitors (AIs) for PEBC. A phase III randomized study explored whether exercise improves arthralgias / myalgias (A/M). Methods: Eligible women with EPBC had A/M related to A and were randomized to an exercise (E) or a control (C) group. E patients exercised 3x weekly for 48 weeks; for the first 12 weeks in a supervised setting; for second 12 weeks, supervised once weekly and twice independently, and for the last 24 weeks independently, using aerobic and resistance programs tailored to their fitness. The primary endpoint was change in SF36 bodily pain domain scores at week 12 (W12). Secondary endpoints included change in bone density (BMD), change in body mass (BMI), strength, and in hot flash (HF) index. Results: The study closed due to poor accrual after 3 years with 22 (11C 11E) of the planned 72 subjects enrolled at two sites among 98 screened. Among 20 evaluable subjects, baseline media...